Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clin... (minutes. It is ideally suited to both po...)

Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial

Date:12/2/2008

minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza.

In late 2006, the Company formed a strategic alliance with 3M to commercialize rapid infectious disease tests worldwide and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize rapid cardiovascular tests worldwide.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or informati
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy
2. FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
3. Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governors Plea to Help the States Population in Need
4. Zimbabwean Health Workers Call For Crisis Response
5. TV News Story on Canine Cancer Generates Dog Lover Response - No. 1 Health Issue for Americas 40 Million Dog-Owning Households
6. iMedExchange Responses to Financial Crisis
7. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
8. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
9. Response Biomedical Closes $5.1 Million Financing
10. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
11. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference

Post Your Comments:

Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clin...(minutes. It is ideally suited to both po...),Health